Keytruda plus chemotherapy meets co-primary endpoint in KEYNOTE-522 trial

This article was originally published here

In the late-stage trial called KEYNOTE-522, Keytruda and chemotherapy combination achieved pathological complete response (pCR) following the neoadjuvant part of the neoadjuvant/adjuvant study regimen. pCR is defined as

The post Keytruda plus chemotherapy meets co-primary endpoint in KEYNOTE-522 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply